The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
Read More
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Read More
Cost regulators for NHS treatments in Scotland have backed six medicines offering new options to some patients with cancer, chronic migraine, high cholesterol and iron deficiency.
Read More
Amgen has presented clinical data indicating that its PCSK9 inhibitor Repatha could help to reverse heart disease by removing atherosclerotic plaques, showing for the first time that the effect of this class of drugs may go further than reducing cholesterol alone.
Read More
NICE has published new guidelines endorsing NHS use of five medicines, widening treatment options for some patients with lung cancer, high cholesterol, melanoma and the skin condition hidradentitis.
Read More
Cost regulators have approved the use of four new medicines for use by NHS Scotland, including a new option for Parkinson’s disease and asthma, but rejected Sanofi-Genzyme’s Jevtana for prostate cancer and Amgen’s Repatha for high cholesterol.
Read More
